Related Experiment Video
Updated: Aug 8, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
Antifungal drug resistance: limited data, dramatic impact?
1Department of Clinical Microbiology, Trinity College Dublin, St. James's Hospital, Ireland. rogerstr@tcd.ie
Abstract:
As the clinical use of antifungal agents continues to grow, the spectre of antifungal drug resistance inevitably emerges. This has been most evident with the extensive prescription of fluconazole in HIV-positive patients. In other settings, there has also been concern over changing patterns in the epidemiology of Candida infections related to fluconazole use. There have been some observations on how new antifungals such as voriconazole and caspofungin are impacting the shift in pathogens and drug resistance. For lipid formulations of amphotericin B, drug resistance is uncommon. Although antifungal drug susceptibility tests for Candida spp. are becoming increasingly standardized, there are limited data that confirm a link between in vitro resistance and treatment failure. Hence, more evidence-based data are needed. This paper examines some of the data on antifungal resistance and briefly explores suitable clinical management strategies for treating fungal infections.
Insights
Antifungal drug resistance is a growing concern, particularly with fluconazole use in HIV patients. This review examines antifungal resistance patterns and management strategies for fungal infections.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Pharmacology
Background:
- Increasing clinical use of antifungal agents raises concerns about emerging drug resistance.
- Fluconazole resistance is notable in HIV-positive patients, impacting Candida infection epidemiology.
- Emerging antifungals like voriconazole and caspofungin show varying effects on pathogen shifts and resistance.
Purpose of the Study:
- To examine current data on antifungal drug resistance.
- To explore clinical management strategies for fungal infections in light of resistance.
- To highlight the need for more evidence linking in vitro resistance to clinical outcomes.
Main Methods:
- Review of existing literature on antifungal drug resistance.
- Analysis of epidemiological shifts in Candida infections.
- Discussion of clinical management approaches.
Main Results:
- Antifungal resistance is a significant clinical challenge, particularly with fluconazole.
- Lipid formulations of amphotericin B demonstrate uncommon drug resistance.
- Standardized susceptibility testing for Candida spp. exists, but data linking in vitro resistance to treatment failure are limited.
Conclusions:
- Further evidence-based data are crucial to confirm the link between in vitro antifungal resistance and clinical treatment failure.
- Effective clinical management strategies are needed to address the growing threat of antifungal resistance.
- Monitoring resistance patterns and judicious use of antifungals are essential for patient care.
Related Concept Videos
Antifungal Agents
Antimicrobial Effectiveness
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Cryptococcal Meningitis
Candidiasis
Clinical Significance of Antibiotic Resistance

